Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
SAGE - Sage Therapeutics Inc
$91.38
-5.38(-5.56%)9:00:00 PM 1/15/2021
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Stock Chart

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • MACD is crossing MACD signal line at 0.3. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/7/2021SAGE
    Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference

    Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that Chief Executive Officer, Barry Greene, will discuss the Company’s progress in becoming a leader in brain health in a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference. As part of the presentation, Mr. Greene will highlight the Company’s planned portfo...

    01/4/2021SAGE
    Benzinga's Top Upgrades, Downgrades For January 4, 2021

    Upgrades * B of A Securities upgraded the previous rating for Expedia Group Inc (NASDAQ:EXPE) from Neutral to Buy. For the third quarter, Expedia Group had an EPS of $0.24, compared to year-ago quarter EPS of $3.37. At the moment, the stock has a 52-week-high of $134.09 and a 52-week-low of $40.76. Expedia Group closed at $132.40 at the end of the last trading period. * According to Evercore ISI Group, the prior rating for Zimmer Biomet Holdings Inc (NYSE:ZBH) was changed from In-Line to Outp...

    12/23/2020SAGE
    Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

    Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET.

    12/22/2020SAGE
    Is SAGE A Good Stock To Buy According To Hedge Funds?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]

    12/20/2020SAGE
    Industry Analysts Just Upgraded Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Forecasts By 23%

    Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders will have a reason to smile today, with the analysts making...

    12/19/2020SAGE
    Should You Buy Sage Stock After the Biogen Investment?

    Each company has suffered a clinical failure recently, but this team-up could do good things for both.

    12/18/2020SAGE
    Where Will Biogen Be in 5 Years?

    This biotech giant is getting desperate to generate sales growth. Should investors be hopeful for a potential turnaround?

    12/16/2020SAGE
    Sage Therapeutics Announces the Appointment of Barry Greene as CEO

    Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that, as part of the Company’s plan to accelerate growth and leverage the talents of the leaders in the brain health space, Barry Greene has been appointed chief executive officer. Mr. Greene, who most recently served as president of Alnylam Pharmaceuticals, Inc., from 2007 to September 2020, a...